CHCornelia Haug

Cornelia Haug

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cornelia Haug has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Adolf Gruenert

    Institute of Clinical Chemistry, University Hospital Ulm, Robert-Koch-Strasse 8, D-89070 Ulm, Germany

    8 shared publications
  • Alexandra Schmid-Kotsas

    Institute of Clinical Chemistry, University Hospital Ulm, Robert-Koch-Strasse 8, D-89070 Ulm, Germany

    5 shared publications
  • Max G. Bachem

    From the Central Department of Clinical Chemistry (C.H., C.L., F.D., M.G.B.), University Hospital Ulm, Germany; and the Laboratory of Molecular Biology (F.D.), Faculty of Medicine, Catholic University of Santisima. Concepción, Chile

    4 shared publications
  • Eva Rozdzinski

    Department of Medical Microbiology, University Hospital Ulm, Robert-Koch-Strasse 8, D-89070 Ulm, Germany

    3 shared publications
  • Christina Lenz

    2 shared publications
  • Max Georg Bachem

    2 shared publications

Latest Publications

  • Oxidized Low-Density Lipoproteins Stimulate Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Release by Coronary Smooth Muscle Cells

    by Cornelia Haug, Christina Lenz, Fredy Díaz, Max G. Bachem

    Objective—Matrix metalloproteinases (MMPs) seem to play a prominent role in atherogenesis. Extracellular MMP inducer (EMMPRIN), a cell surface glycoprotein which stimulates MMP synthesis, has recently been detected in human atheroma. We have investigated the influence of oxidized low-density lipoproteins (oxLDLs) on EMMPRIN expression in human coronary artery smooth muscle cells (HCA-SMCs).Methods and Results—OxLDL induced a significant increase of EMMPRIN release into HCA-SMC supernatants and a concomitant decrease of cell-associated EMMPRIN. These effects were antagonized by antioxidants as well as by EDTA and the MMP inhibitor GM6001. Western blot analysis demonstrated that MMP-1 and MMP-2 induce the cleavage of the extracellular domain from cell-associated EMMPRIN. MMP-1 and MMP-2 synthesis was upregulated by oxLDL, and, in addition, we have shown that soluble EMMPRIN, isolated from macrophage supernatants, increased MMP-1 and MMP-2 synthesis in HCA-SMC.Conclusion—Our data suggest that oxLDLs stimulate the release of soluble EMMPRIN, at least in part, by MMP-dependent shedding from the cell surface. Additionally, oxLDLs might induce a circular upregulation of matrix degradation because, in turn, soluble EMMPRIN stimulates MMP synthesis in HCA-SMC.


  • The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells

    by Cornelia Haug, Alexandra Schmid-Kotsas, Theresia Linder, Peter M. Jehle, Max G. Bachem, Adolf Gruenert, Eva Rozdzinski

    Several studies have demonstrated that endothelin-1 (ET-1) plays an important pathophysiological role in ischaemic renal failure and drug-induced renal injury, such as cyclosporine A (CsA)- and tacrolimus-associated nephrotoxicity. This study aimed to investigate whether the new immunosuppressive drug mycophenolic acid (MPA), which in contrast with CsA and tacrolimus lacks nephrotoxic side effects, modulates ET-1 synthesis in endothelial cells and renal epithelial cells. ET-1 release by cultured human umbilical vein endothelial cells (HUVEC), human renal artery endothelial cells (RAEC) and rabbit proximal tubule cells was measured with a specific ELISA. ET-1 mRNA expression was investigated by reverse transcription–PCR. MPA (2.5–50µg/ml) induced a significant decrease in ET-1 mRNA expression (minimum 51.8±3.8% of control; Pµg/ml), a significant decrease in ET-1 release per culture well (minimum 56.8±1.7%; PPP<0.05). This study provides evidence that, in contrast with CsA and tacrolimus, MPA does not stimulate ET-1 synthesis. The present results might explain the clinical observation that renal function often improves when CsA or tacrolimus is replaced by mycophenolate mofetil.


  • Evaluation of Two Modified Cardiac Troponin I Enzyme Immunoassays

    by Cornelia Haug, Max G. Bachem, Holger Woehrle, Martin Hetzel, Adolf Gruenert

    One of the major challenges for manufacturers of troponin immunoassays is to optimize the low-end of the assays because diagnostic and therapeutic interventions are based on decreasing cutpoints. Recently published consensus documents of the European Society of Cardiology and the American College of Cardiology recommended the 99th percentile of a reference control group as cut-off for increased troponin I levels and suggested that imprecision at the 99th percentile for each assay should be < or = 10%. In this study, we have evaluated two newly modified cardiac troponin I (cTnI) enzyme immunoassays (Dimension cTnI assay, Dade Behring, Germany and AIA-PACK cTnI 2nd-Gen, Eurogenetics Tosoh, Belgium). With both assays all measured cTnI values in plasma and serum samples of apparently healthy volunteers were within the reference ranges given by the manufacturers. Intra-assay coefficients of variation of cTnI concentrations above the 99th percentile (given by the manufacturers) were below 17% and decreased with increasing cTnI concentrations. In most samples, the AIA-PACK cTnI assay yielded higher results; however, a close correlation between both assays was observed. Both tests exhibit acceptable overall performance, but (especially the Dimension cTnI assay) do not yet meet the above-mentioned precision in the low-end assay range. These data emphasize the need for cTnI assay standardization and for further optimization at clinical decision levels.


  • Open Access

    Influence of hepatocyte growth factor, epidermal growth factor, and mycophenolic acid on endothelin‐1 synthesis in human endothelial cells

    by Cornelia Haug, Alexandra Schmid‐Kotsas, Theresia Linder, Max G. Bachem, Adolf Gruenert, Eva Rozdzinski

    Background. Endothelin‐1 (ET‐1) is a potent vasoconstrictive peptide which plays an important pathophysiological role in ischaemic renal failure and drug‐induced renal injury such as cyclosporin A (CsA)‐ and tacrolimus‐associated nephrotoxicity. In contrast, hepatocyte growth factor (HGF) and epidermal growth factor (EGF) seem to accelerate renal regeneration after ischaemic and drug‐induced renal injury. This study aimed to investigate the influence of HGF and EGF on ET‐1 synthesis in cultured human umbilical vein endothelial cells (HUVEC) and renal artery endothelial cells (RAEC). In addition, we have investigated whether mycophenolic acid (MPA), a new immunosuppressive drug, which in contrast to CsA and tacrolimus lacks nephrotoxic side effects, modulates ET‐1 synthesis in endothelial cells. Methods. ET‐1 release was measured with a specific enzyme‐linked immunosorbent assay. ET‐1 mRNA expression was investigated by reverse transcription polymerase chain reaction. Results. HGF and EGF (0.001−10 nM) exerted a significant concentration‐dependent inhibitory effect on ET‐1 release by HUVEC and RAEC (minimum 56.1±4.3% of control, n=6, mean±SE). The suppressive effect of HGF and EGF on ET‐1 synthesis was dose‐dependently antagonized by the tyrosine kinase inhibitors tyrphostin AG1478, lavendustin A and methyl 2,5‐dihydroxycinnamate. Incubation of HUVEC and RAEC with MPA (2.5, 10, 25, and 50 μg/ml) for 3–5 h induced a significant reduction of ET‐1 mRNA expression. After 48 h incubation with MPA (1–50 μg/ml) a significant decrease of ET‐1 release and DNA content per culture well was observed, whereas ET‐1 release referred to the DNA content in the corresponding culture well did not differ significantly from controls. Conclusions. The present findings demonstrate that HGF and EGF reduce ET‐1 synthesis in endothelial cells via their receptor tyrosine kinase activity and suggest that the renoprotective effects of HGF and EGF might be linked to their inhibitory action on ET‐1 synthesis. This study also provides evidence that, in contrast to CsA and tacrolimus, MPA does not stimulate ET‐1 synthesis. This might explain the clinical observation that renal function often improves when CsA or tacrolimus is replaced by mycophenolate mofetil.


  • Hepatocyte growth factor is upregulated by low-density lipoproteins and inhibits endothelin-1 release

    by Cornelia Haug, Alexandra Schmid-Kotsas, Ulrike Zorn, Max G. Bachem, Sabine Schuett, Adolf Gruenert, Eva Rozdzinski, Silvia Kelsen, John E. Hall, Alejandro R. Chade, et al.

    Low-density lipoproteins (LDL) are known to cause endothelial injury and to promote the development of atherosclerotic lesions. This study demonstrates a significant concentration-dependent stimulatory effect of LDL on hepatocyte growth factor (HGF) synthesis (maximum release: 423 ± 16% of control) and HGF receptor mRNA expression in cultured human coronary artery endothelial cells (HCAEC). HGF is a potent mitogen for endothelial cells but does not affect smooth muscle cell proliferation. In contrast, endothelin-1 (ET-1) acts as a mitogen on vascular smooth muscle cells and seems to be upregulated in coronary atherosclerosis. In this study, the basal ET-1 synthesis in HCAEC was concentration-dependently reduced by HGF (minimum: 54 ± 3% of control). This inhibitory effect seems to be mediated via the tyrosine kinase activity of the HGF receptor c-met, since it was antagonized by the tyrosine kinase inhibitor lavendustin A. In addition, HGF also significantly reduced the LDL-stimulated ET-1 release. The LDL-induced upregulation of HGF synthesis in HCAEC and the inhibitory effect of HGF on ET-1 synthesis suggest a protective role of HGF in coronary atherosclerosis.


  • Inhibitory Effect of Epidermal Growth Factor and Hepatocyte Growth Factor on Endothelin-1 Release by Rabbit Proximal Tubule Cells

    by Cornelia Haug, Theresia M. Linder, Alexandra Schmid-Kotsas, Simone Hetzel, Friedlinde Ernst, Adolf Gruenert, Peter M. Jehle

    Several studies have demonstrated an upregulation of endothelin-1 (ET-1) synthesis in acute and chronic renal failure. Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) have been shown to stimulate renal tubular cell proliferation and to accelerate renal regeneration after drug-induced and ischemia-induced renal injury. This study aimed to investigate the effect of EGF and HGF on ET-1 release, and whether the effect of EGF and HGF is antagonized by the tyrosine kinase inhibitor lavendustin A. Rabbit proximal tubule cells were incubated for 48 h with EGF or HGF (0.1-10.0 nM), lavendustin A (0.1-10.0 microM) or co-incubated with EGF or HGF (1 nM) and lavendustin A. ET-1 concentrations in the culture medium were measured with a specific enzyme-linked immunosorbent assay (ELISA). EGF and HGF exerted a significant (p < 0.001) dose-dependent inhibitory effect on ET-1 release. Lavendustin A induced a dose-dependent stimulation of ET-1 release and antagonized the inhibitory effect of EGF and HGF on ET-1 release. The inhibition of EGF and HGF receptor tyrosine kinase activity by lavendustin A was confirmed by Western blotting. These data suggest that EGF and HGF reduce ET-1 release via EGF and HGF receptor tyrosine kinase activity. The inhibitory action of EGF and HGF on ET-1 release might be involved in mediating the protective effects of EGF and HGF in renal injury.


  • Endothelin release by rabbit proximal tubule cells: Modulatory effects of cyclosporine A, tacrolimus, HGF and EGF

    by Cornelia Haug, Christian Grill, Alexandra Schmid-Kotsas, Adolf Gruenert, Peter Michael Jehle


  • Open Access

    Direct enzyme immunometric measurement of plasma big endothelin-1 concentrations and correlation with indicators of left ventricular function

    by Cornelia Haug, Wolfgang Koenig, Martin Hoeher, Matthias Kochs, Vinzenz Hombach, Adolf Gruenert, Hans Osterhues

    Recent studies have suggested that the plasma concentrations of endothelin-1, a potent vasoconstrictive peptide, are increased in patients with congestive heart failure. This study aimed to evaluate a new direct ELISA for big endothelin-1 (the precursor of endothelin-1), in comparison with a big endothelin-1 ELISA using plasma sample extraction, and to investigate whether plasma big endothelin-1 concentrations correlate with indicators of left ventricular function. The direct ELISA yielded significantly (P r = 0.86, P P r = −0.46, r = −0.40) with the left ventricular ejection fraction and a significant positive correlation (r = 0.40, P r = 0.36, P r = 0.42, r = 0.38, P r = 0.52, r = 0.47, P <0.001) volume indices. Plasma big endothelin-1 concentrations were notably greater in patients with New York Heart Association (NYHA) class II–IV symptoms than in patients without cardiac disease or in patients categorized to NYHA class I. These data suggest that plasma big endothelin-1 concentrations, measured by a direct ELISA, correlate with hemodynamic indicators and symptoms of left ventricular dysfunction.